Methods for the modulation of angiogenesis

Abstract

The present invention relates to methods and compositions for promoting or inhibiting capillary endothelial (CE) cell migration, promoting or inhibiting the formation of CE networks and promoting or inhibiting angiogenesis. Some embodiments relate to methods and compositions for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. One aspect relates to the use of at least one pro-angiogenic agent selected from at least one of an p190RhoGAP inhibitor, a TFII-I inhibitor a GATA-2 activator for promoting the formation of CE networks and angiogenesis, and methods for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. Another aspect of the invention related to use of at least one anti-angiogenic agent selected from at least one of an p190RhoGAP activator, a TFII-I activator a GATA-2 inhibitor for inhibiting the formation of CE networks and inhibiting angiogenesis, and methods for treating angiogenesis-related disorders characterized by uncontrolled or elevated angiogenesis.

What is claimed: 
     
         1 . A pharmaceutical composition comprising a therapeutically effective amount of at least one anti-angiogenic agent selected from the group consisting of: a p190RhoGAP activator, a TFII-I activator, a GATA-2 inhibitor, and a pharmaceutically acceptable carrier. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the GATA-2 inhibitor is selected from the group consisting of an antibody, an RNA interference molecule, a small molecule, a peptide and an aptamer. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the p190RhoGAP activator the TFII-I activator is selected from the group consisting of an antibody, a small molecule, a peptide, polypeptide, or nucleic acid. 
     
     
         4 . The pharmaceutical composition of  claim 1 , further comprising at least one additional anti-angiogenic therapy.